Step by Step


ABIM MOC Activity ID

10/19/2021 - Medical Grand Rounds: Rheumatology and Clinical Immunology Year in Review





Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Tocilizumab in systemic sclerosis related interstitial lung disease: the data behind this new FDA approved indication
Presented by: Robyn Domsic, MD, MPH

IVIG in Dermatomyositis
Presented by: Rohit Aggarwal, MD, MS

Accelerating Medicine Partnership in Rheumatoid Arthritis and Lupus - overview and research findings
Presented by: Mandy McGeachy, PhD

Updates in Vasculitis
Presented by: Sebastian Sattui, MD, MS

Educational Objectives:

Upon completion of this activity, participants should be able to:
  • Explain the efficacy of IVIG in dermatomyositis
  • Describe the safety and monitoring of IVIG in dermatomyositis.
  • Learn that tocilizumab is now approved for the management of scleroderma-related ILD.
  • Recognize that all trial data currently is in patients with diffuse scleroderma
  • Explain where tocilizumab may fit into scleroderma lung disease management
  • Review NIH-industry funded U-grant mechanism for clinical research studies
  • Examine the Accelerating Medicines Partnership (AMP) in RA and lupus study procedures and goals
  • Increase recognition and diagnosis of a new syndrome characterized by somatic mutations, hematologic abnormalities and inflammatory manifestations.
  • Review the indication for use of plasmapheresis in patients with ANCA-associated vasculitis based on new information from a recent RCT
  • Review literature showing reduced glucocorticoid use and improved outcomes in patients with ANCA vasculitis.
  • Discuss evidence behind C5a inhibition as a novel therapeutic in the management of ANCA vasculitis.

Suggested Additional Reading & Joint Accreditation Statement - Note: This Accreditation Statement Supersedes All Other Statements:

Suggested additional reading:

  1. Khanna D., Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016;387:2630–40
  2. Khanna et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 2018;77:212–220.
  3. Khanna D., Lin CJF, Furst DE et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med . 2020 Oct;8(10):963-974
  4. Methods for high-dimensional analysis of cells dissociated from cryopreserved synovial tissue. Donlin LT, Rao DA, Wei K, Slowikowski K, et al. Arthritis Res Ther. 2018 Jul 11;20(1):139. doi: 10.1186/s13075-018-1631-y.PMID: 29996944
  5. Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. Deonaraine KK, Carlucci PM, Fava A, et al. Lupus Sci Med. 2021 Aug;8(1):e000522. doi: 10.1136/lupus-2021-000522.PMID: 34389634
  6. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Zhang F, Wei K, Slowikowski K, et al.Nat Immunol. 2019 Jul;20(7):928-942. doi: 10.1038/s41590-019-0378-1. Epub 2019 May 6. PMID: 31061532
  7. Beck DB, et al. Somatic mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med 2020; 383:2628-2638
  8. Walsh M, et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl. J Med 2020; 382:622-631
  9. Furuta S, et al. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. JAMA. 2021; 325 (21):2178
  10. Jayne DRW, et al. Avacopan for the Treatment of ANCA-associated Vasculitis. N Engl J Med 2021; 384:599-609

Joint Accreditation Statement
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit[s]™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This educational activity is approved for 1.0 contact hours.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Mandy McGeachy, PhD — Associate Professor of Medicine, Division of Rheumatology and Clinical Immunology
University of Pittsburgh School of Medicine
No relationships with industry relevant to the content of this educational activity have been disclosed.
Robyn Domsic, MD, MPH — Associate Professor of Medicine, Division of Rheumatology and Clinical Immunology University of Pittsburgh School of Medicine
Dr. Domsic is a consultant for CSL Behring, Aisa Pharmaceuticals.
Rohit Aggarwal, MD, MS — Professor of Medicine, Division of Rheumatology and Clinical Immunology
Medical Director, Arthritis and Autoimmunity Center
University of Pittsburgh School of Medicine
Dr. Aggarwal receives grant/research support from Genentech, Mallinckrodt, BMS, EMD Serono, Q32. He is a consultant for Kezar, Pfizer, AstraZeneca, Alexion, Argenx, BI, BMS, Q32, Corbus, Janssen, Kyverna, Octapharma, and CSH Behring. He is an Advisory Board member for Oraphazyme, Mallinckrodt, Octopharma, and CHS Behring.
Sebastian Sattui, MD, MS — Assistant Professor of Medicine, Division of Rheumatology and Clinical Immunology
University of Pittsburgh School of Medicine
Dr. Sattui receives support from the Vasculitis Foundation and Vasculitis Clinical Research Consortium through the VF/VCRC Fellowship award.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.